
Profound Medical Corp. PROF
$ 7.26
5.99%
Profound Medical Corp. Book Value | PROF
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Profound Medical Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 66.4 M | 60.4 M | 31.2 M | 52 M | 80.6 M | 97.4 M | - | - | 14.1 M | 11 M | 10.1 M | 1.37 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 97.4 M | 1.37 M | 42.5 M |
Quarterly Book Value Profound Medical Corp.
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2023-Q4 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 59.4 M | 32.1 M | 39.3 M | 50.8 M | 31.2 M | - | - | - | - | 80.6 M | - | - | - | 97.4 M | - | - | - | 14.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 97.4 M | 14.4 M | 50.6 M |
Book Value of other stocks in the Medical devices industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Cutera
CUTR
|
-172 M | - | -10.19 % | $ 1.99 M | ||
|
EDAP TMS S.A.
EDAP
|
40.9 M | - | - | $ 162 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
196 M | - | - | $ 1.77 B | ||
|
Avinger
AVGR
|
-6.2 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
638 M | - | - | $ 3.31 B | ||
|
Eargo
EAR
|
101 M | - | - | $ 10.2 M | ||
|
Lianluo Smart Limited
LLIT
|
272 M | - | 24.59 % | $ 44.8 M | ||
|
LENSAR
LNSR
|
-12.2 M | $ 5.6 | -2.78 % | $ 67 M | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
25.5 M | - | -5.86 % | $ 30.6 M | ||
|
Apollo Endosurgery
APEN
|
32.6 M | - | - | $ 475 M | ||
|
Aziyo Biologics
AZYO
|
27.7 M | - | 1.37 % | $ 20.5 M | ||
|
BioSig Technologies
BSGM
|
133 M | - | 37.08 % | $ 85.7 M | ||
|
BIOLASE
BIOL
|
1.96 M | - | -13.19 % | $ 166 K | ||
|
Outset Medical
OM
|
127 M | $ 4.04 | -4.49 % | $ 61.5 K | ||
|
AxoGen
AXGN
|
129 M | $ 39.49 | -0.6 % | $ 1.82 B | ||
|
Conformis
CFMS
|
54.2 M | - | - | $ 16.4 M | ||
|
Insulet Corporation
PODD
|
1.52 B | $ 163.26 | 3.08 % | $ 11.5 B | ||
|
Cardiovascular Systems
CSII
|
249 M | - | 0.15 % | $ 844 M | ||
|
Quanterix Corporation
QTRX
|
296 M | $ 3.67 | -6.38 % | $ 156 M | ||
|
CryoLife, Inc.
CRY
|
58.1 M | - | -4.14 % | $ 702 M | ||
|
Bruker Corporation
BRKR
|
2.51 B | $ 60.45 | -2.74 % | $ 9.18 B | ||
|
CHF Solutions, Inc.
CHFS
|
6.23 M | - | 1.15 % | $ 34.5 M | ||
|
Sintx Technologies
SINT
|
2.93 M | $ 1.42 | -6.58 % | $ 3.94 M | ||
|
Soliton, Inc.
SOLY
|
243 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
2.61 B | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
229 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
30.4 M | - | - | $ 462 M | ||
|
TELA Bio
TELA
|
6.31 M | $ 0.69 | -2.81 % | $ 32.4 M | ||
|
Neovasc
NVCN
|
52.2 M | - | - | $ 111 M | ||
|
Dynatronics Corporation
DYNT
|
3.26 M | - | 14.99 % | $ 929 K | ||
|
Tactile Systems Technology
TCMD
|
219 M | $ 27.48 | 0.15 % | $ 629 M | ||
|
TransMedics Group
TMDX
|
473 M | $ 72.26 | 1.59 % | $ 2.46 B | ||
|
IRIDEX Corporation
IRIX
|
4.92 M | $ 0.89 | -3.38 % | $ 15.1 M | ||
|
Tandem Diabetes Care
TNDM
|
155 M | $ 17.12 | 1.3 % | $ 1.16 B | ||
|
Intersect ENT, Inc.
XENT
|
550 M | - | - | $ 955 M | ||
|
Second Sight Medical Products
EYES
|
15.7 M | - | -0.97 % | $ 54.4 M | ||
|
GBS
GBS
|
2.81 M | - | -0.57 % | $ 7.12 M | ||
|
ClearPoint Neuro
CLPT
|
28 M | $ 14.12 | -2.55 % | $ 400 M | ||
|
Viemed Healthcare
VMD
|
144 M | $ 11.77 | 0.86 % | $ 458 M | ||
|
Avanos Medical
AVNS
|
778 M | $ 24.99 | 0.04 % | $ 1.16 B | ||
|
Beyond Air
XAIR
|
6.21 M | $ 5.16 | -5.67 % | $ 42.8 B | ||
|
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | ||
|
Xtant Medical Holdings
XTNT
|
51 M | $ 0.43 | -0.39 % | $ 60 M | ||
|
Cytosorbents Corporation
CTSO
|
5.9 M | $ 0.36 | -0.39 % | $ 22.4 M | ||
|
NanoVibronix
NAOV
|
33.5 M | - | - | $ 1.08 M | ||
|
NuVasive
NUVA
|
2.22 B | - | - | $ 2.07 B | ||
|
Natus Medical Incorporated
NTUS
|
425 M | - | 1.94 % | $ 1.05 B | ||
|
Nevro Corp.
NVRO
|
231 M | - | - | $ 217 M | ||
|
Inogen
INGN
|
192 M | $ 6.15 | -2.69 % | $ 164 M |